Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $68.6667.

A number of brokerages have recently weighed in on GPCR. Guggenheim dropped their price target on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Lifesci Capital upgraded Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $30.07 on Friday. The company has a market capitalization of $1.73 billion, a PE ratio of -28.64 and a beta of -1.65. The company has a 50-day simple moving average of $21.74 and a two-hundred day simple moving average of $21.23. Structure Therapeutics has a one year low of $13.22 and a one year high of $42.57.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). On average, equities analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Large investors have recently bought and sold shares of the company. State of Wyoming purchased a new stake in Structure Therapeutics in the second quarter valued at approximately $28,000. National Bank of Canada FI boosted its position in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after buying an additional 2,766 shares during the last quarter. Assetmark Inc. boosted its position in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after buying an additional 3,213 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.